Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;42(8):e70052.
doi: 10.1111/dme.70052. Epub 2025 Jun 3.

Weight loss is associated with improved daytime time in range in adults with prediabetes and non-insulin-treated type 2 diabetes undergoing dietary intervention

Souptik Barua  1 , Dhairya Upadhyay  1 , Lauren T Berube  2   3 , Collin J Popp  3 , Margaret Curran  3 , Mary Lou Pompeii  3 , Lu Hu  3 , Jose O Aleman  4 , Michael Bergman  3   4 , Mary Ann Sevick  3
Affiliations

Weight loss is associated with improved daytime time in range in adults with prediabetes and non-insulin-treated type 2 diabetes undergoing dietary intervention

Souptik Barua et al. Diabet Med. 2025 Aug.

Abstract

Aims: To characterize changes in continuous glucose monitoring (CGM)-derived time in tight range (TIR) measures in individuals with prediabetes or non-insulin-treated type 2 diabetes undergoing dietary weight loss intervention and to quantify the association between weight loss and TIR improvement.

Methods: Data from the Personal Diet Study, a 6-month behavioural weight loss intervention in adults with prediabetes or non-insulin-treated type 2 diabetes [HbA1c ≤ 8.0% (64 mmol/mol), managed with diet alone or with metformin], was analysed. Participants wore a CGM for a maximum of 2 weeks at baseline and 6 months. Changes in overall, daytime (06:00 h-23:59 h) and overnight (00:00 h-05:59 h) time in 54-140 mg/dL or 3.0-7.8 mmol/L (TIR54-140), 70-140 mg/dL or 3.9-7.8 mmol/L (TIR70-140) and >140 mg/dL or >7.8 mmol/L (TAR>140) were analysed. The association between weight change and TIR change adjusted for demographic and clinical covariates was computed using linear regression.

Results: Baseline and 6 months CGM data from 76 participants (63 ± 8 years, 62% female, 64% White, BMI 33 ± 5 kg/m2, HbA1c 5.8 ± 0.6%) were analysed. Overall TIR54-140 increased (3.3% [0.3, 6.3]%; p = 0.03), with improvement in daytime (3.8% [0.9, 6.8]%; p = 0.01) but not overnight TIR54-140 (2.0% [-2.2, 6.1]%; p = 0.36). In adjusted analysis, every 5% points of weight loss was associated with a 3.2% points increase in overall TIR54-140 (p = 0.016), driven by a 3.5% points increase in daytime TIR54-140 (p = 0.006). Similar associations were found for TAR>140 but not TIR70-140. There were no associations between weight loss and change in any overnight TIR measure.

Conclusion: Weight loss was associated with improved daytime TIR54-140 and TAR>140 in individuals with prediabetes and non-insulin-treated type 2 diabetes undergoing dietary intervention. The daytime time in tight range measures can complement traditional markers like HbA1c, offering a more comprehensive view of glycaemic variations during dietary weight loss programmes for individuals with prediabetes and type 2 diabetes not on insulin.

Keywords: type 2 diabetes.

PubMed Disclaimer

References

REFERENCES

    1. Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA. 2017;317:379‐387. doi:10.1001/jama.2016.19976
    1. Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE‐BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well‐controlled type 1 diabetes. Diabetes Care. 2017;40:538‐545. doi:10.2337/dc16-2482
    1. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual Care in Patients with Type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167:365‐374. doi:10.7326/M16-2855
    1. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42:400‐405. doi:10.2337/dc18-1444
    1. Yang J, Yang X, Zhao D, Wang X, Wei W, Yuan H. Association of time in range, as assessed by continuous glucose monitoring, with painful diabetic polyneuropathy. J Diabetes Investig. 2021;12:828‐836. doi:10.1111/jdi.13394